REVIEW

Refractory symptoms in paediatric palliative care: can ketamine help?

Franca Benini¹, Sabrina Congedi¹, Luca Giacomelli², Simonetta Papa², Aashni Shah², Gregorio Milani³,⁴

¹Centro Regionale Veneto di Terapia del Dolore and Cure Palliative Pediatriche, Hospice Pediatrico, Padua, Italy; ²Polistudium SRL, Milan, Italy; ³Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy; ⁴Pediatric Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

Abstract

**Background:** One of the main challenges for paediatric palliative care (PPC) is the management of concomitant, different and severe symptoms that frequently affect the quality of life of PPC patients and are often refractory to commonly used pharmacological treatments. Consequently, many efforts are still needed to find the best therapeutic options to handle these refractory conditions. Since the first synthesis of ketamine in the 1960s, its pharmacokinetic and pharmacodynamic properties have been largely investigated and its potential wide range of clinical applications has become clear. However, this molecule still receives poor attention in some areas, including in children and PPC. This narrative review analyses the use of ketamine in children and the potential extension of its applications in PPC in order to provide new options for treatment in the PPC setting.

**Methods:** Scientific papers published before October 2020 on MEDLINE, EMBASE and the Cochrane Library were considered. The cited references of the selected papers and the authors’ personal collections of literature were reviewed. The terms “palliative care”, “ketamine”, “neuropathic pain”, “procedural pain”, “status epilepticus”, “refractory pain” and “child”, adding “age: birth–18 years” on a further filter were used for the search.

**Discussion:** The use of ketamine in PPC should be more widely considered due to its overall favourable safety profile and its efficacy, which are supported by an increasing number of studies, although in settings different from PPC and of mixed quality. Ketamine should be proposed according to a case-by-case evaluation and the specific diagnosis and the dosage and route of administration should be tailored to the specific needs of patients. Furthermore, there is evidence to suggest that ketamine is safe and efficacious in acute pain. These findings can prompt further research on the use of ketamine for the treatment of acute pain in PPC.

**Conclusion:** Ketamine could be a suitable option after the failure of conventional drugs in the treatment of different refractory conditions in PPC.

**Keywords:** children, clinical needs, ketamine, paediatric palliative care.

Citation

Benini F, Congedi S, Giacomelli L, Papa S, Shah A, Milani G. Refractory symptoms in paediatric palliative care: can ketamine help? Drugs in Context 2021; 10: 2021-2-5. DOI: 10.7573/dic.2021-2-5

Introduction

The prevalence of children suffering from life-limiting and life-threatening diseases and disabilities is estimated as 10 per 10,000 children aged 0–19 years.¹,² However, these numbers are increasing worldwide and, due to the medical advances achieved in the last years, the life expectancy of these patients has improved.¹-³ These children have unique and complex needs that often require combined multidisciplinary care, which comes under the umbrella of paediatric palliative care (PPC). The focus of PPC is to ensure the best ‘quality of life’ possible for the child and their family for the entire life span of the patient.³-⁶ One of the main challenges for PPC specialists is the management of multiple severe symptoms and conditions, including chronic pain, seizures and mood alterations, which frequently affect the quality of life of these patients. Unfortunately, these symptoms are sometimes refractory to commonly used pharmacological treatments and most drugs used for their management are prescribed off-label.⁷,⁸ Consequently, many efforts are still needed to find the best therapeutic options to handle these conditions.

Recently, mounting interest has been demonstrated on the use of ketamine in the paediatric setting.⁹ This drug was first
marketed as an anaesthetic drug in 1964. It is a non-competitive, voltage-dependent N-methyl-D-aspartate (NMDA) receptor antagonist. The administration of ketamine reduces the excitatory pathways mediated by the NMDA receptor, inducing a cataleptic and analgesic action without hypnotic properties, which account for the peculiar anaesthetic effect of ketamine. The pharmacological activity of ketamine can be used to induce sedation and somatic analgesia as well as to provide antiepileptic and antidepressive effects. Even if there are few data on its use in this field in paediatric care, its use could be considered in the PPC setting, where complexity and progression of disease make it difficult to control the symptoms and only a partial response to the oldest drugs is often experienced.

This narrative review aims to highlight the current knowledge on the use of ketamine for childcare in different settings, focusing on the actual knowledge and potential extension of its applications in PPC.

Methods

This is a narrative review of studies about the use of ketamine in the paediatric population in different care settings. Scientific papers published before October 2020 on MEDLINE, EMBASE and the Cochrane Library, without any limitations, were considered. The terms “palliative care”, “ketamine”, “neuropathic pain”, “procedural pain”, “status epilepticus”, “refractory pain” and “child”, adding “age: birth–18 years” on a further filter were used for the search. ‘AND’ was also used as a Boolean operator. Moreover, in order to identify relevant studies, the cited references of the selected papers were also reviewed. The authors’ personal collections of literature were also browsed. Papers were selected for consideration in this manuscript according to their relevance for the topic, as judged by the authors.

Ethical approval and informed consent

Given the nature of this study, the project was exempt from institutional review board/ethics committee review.

Review

Ketamine and refractory and/or neuropathic pain

Ketamine, when used in low doses, has antinociceptive effects through the supraspinal blockade of the NR2B NMDA subunit and opioid delta receptor. It also augments the µ-opioid receptor function, an endogenous antinociceptive system. The inhibition of nitric oxide synthase probably also contributes to its analgesic effects but the importance of this mechanism is not well established.

The acute and prolonged effect of ketamine on neuropathic pain is also well known. A single administration of low-dose ketamine, thanks to the inhibition of the NMDA-mediated pathway, can rapidly and transiently reduce neuropathic pain and related symptoms such as allodynia and hyperalgesia. In addition, we can also speculate that ketamine could interact with some opioid tolerance/addiction mechanisms.

These pharmacological properties of ketamine are useful to induce analgesia in the paediatric setting, in particular for children with advanced cancer who often experience stressful symptoms such as neuropathic or mixed pain, which is reported to be the most common type of pain (up to 80%).

Even if there are no randomized controlled trials, the use of ketamine is considered an option for the control of refractory cancer pain and has been investigated in different studies (Table 1). The additional value of this therapeutic approach is that ketamine, in this setting, can also help opioid sparing, avoiding the development of withdrawal symptoms.

Taylor et al. reported a retrospective case series of 14 children in end-of-life treatment complaining of opioid-refractory neuropathic pain and treated with ketamine. Pain relief was referred to by all participants and 79% of patients experienced no adverse effects. A reduction in the use of opioids was also reported in most cases.

Another study analysed the effect of subanaesthetic doses of ketamine used to treat 11 children who were on high doses of opioids and had uncontrolled cancer pain. In the majority of patients, ketamine infusions were associated with opioid-sparing effects and apparent improvement in pain control and in the children’s ability to interact with their family. The same effect was also experienced in end-stage life disease by a 12-year-old woman with a diagnosis of glioblastoma multiforme and by a 2.8-year-old child with metastatic neuroblastoma. Similar results were also reported in other case series.

Sickle cell (SC) disease is the most common haemoglobin variant in the world and can present with recurrent vaso-occlusive painful crises. In adults with SC disease, opioid tolerance and related side effects have been major barriers to adequate pain relief and the use of low-dose ketamine infusions showed promising results for pain relief in this condition.

Considering the paediatric setting, the role and effectiveness of ketamine infusion for a painful SC crisis have been investigated in two recent papers. In a randomized non-inferiority trial, data supported a comparable analgesic effect to treat severe painful SC crisis between intravenous (i.v.) ketamine and equianalgesic i.v. morphine dosage. A literature review highlighted the potential effectiveness of low-dose ketamine infusions for painful SC crisis on the reduction of pain score and opioid dosage (Table 1).

Ketamine and refractory and/or neuropathic pain in PPC: expert opinion

Pain is a common and severe symptom in children undergoing PPC, both in the oncology and non-oncology setting. In these patients, the treatment of pain is a priority.
In the PPC setting, conventional drugs often show a poor efficacy and many side effects. In addition, neuropathic or mixed pain are often difficult to distinguish from each other. Consequently, although current data in the PPC setting are still scant and further studies are necessary to achieve more solid evidence, we believe that ketamine, alone or in combination, could be an option for the management and treatment of mixed or neuropathic pain that do not respond to available first-line drugs.

Another advantage of ketamine is the possibility to use an alternative administration route (intranasal and transmucosal). Indeed, many PPC patients have difficult vascular access and may benefit from another administration route.

### Ketamine and procedural pain

In paediatrics, particularly in the PPC setting, invasive procedures are part of several diagnostic and therapeutic approaches, including surgery, immunization, spinal tap, bone marrow aspiration, needle procedures, and orthopaedic and wound-related injuries. Therefore, the provision of moderate sedo-analgesia before and during an invasive procedure is mandatory. A common practice is to induce general anaesthesia but this possibility is not always available or the best option.\(^{30}\) Due to its sedative and analgesic potential when used after trauma or surgery,\(^ {31}\) ketamine could be used in children for this purpose and its use is now accepted in this setting.\(^ {32-34}\)

### Table 1. Ketamine application for children in paediatric palliative care.

| Type of study                      | Aim                                                                 | Results                                                                 | Ref.   |
|-----------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------------------|--------|
| **Refractory and/or neuropathic pain management** |                                                                      |                                                                         |        |
| Retrospective clinical study      | Evaluation of ketamine treatment for opioid-refractory neuropathic pain | Pain relief; escalation of opioids                                      | Taylor et al.\(^ {22}\) |
| Case series                       | Evaluation of low-dose ketamine in children with terminal cancer who had inadequate pain control and/or had developed serious side effects with opioids | Opioid-sparing effect; improvement in pain control                      | Finkel et al.\(^ {23}\) |
| Case series                       | Evaluation of continuous low-dose infusion ketamine in children with intractable end-stage cancer pain | Opioid-sparing effect; improvement in pain control                      | Conway et al.\(^ {25}\) |
| Case report                       | Evaluation of ketamine analgesic effect in a 12-year-old girl suffering from glioblastoma multiforme | Opioid-sparing effect; improvement in pain control                      | Klepstad et al.\(^ {24}\) |
| Case report                       | Evaluation of ketamine analgesic effect in a 2.8-year-old child with severe pain from metastatic neuroblastoma | Opioid-sparing effect; improvement in pain control                      | Tsui et al.\(^ {26}\) |
| Randomized controlled trial       | Evaluation of the effectiveness of ketamine infusion for painful sickle cell disease crisis | Comparative analgesic effect of ketamine and morphine infusions has been observed | Lubega et al.\(^ {28}\) |
| Observational study               | Evaluation of ketamine tolerance and satisfaction as an adjuvant analgesic for refractory cancer pain | Low doses of ketamine as an adjuvant to opioids significantly reduced the intensity of pain in half of the study population \((p<0.001)\) | Courade et al.\(^ {19}\) |
| **Procedural pain management**    |                                                                      |                                                                         |        |
| Clinical trial                    | Evaluation of rectal administration of ketamine in children with cerebral palsy | Moderate sedation and analgesia were achieved                           | Nilsson et al.\(^ {41}\) |
| **Status epilepticus management** |                                                                      |                                                                         |        |
| Retrospective clinical study      | Evaluation of ketamine treatment to manage refractory status epilepticus in children in intensive care unit | Refractory status epilepticus was controlled with ketamine in the majority of patients, showing a significantly greater effectiveness in the loading-maintenance protocol compared to the maintenance group | Wu et al.\(^ {58}\) |
In the paediatric emergency department (ED) in the United States and Europe, the use of ketamine for procedural sedoanalgesia is a common procedure, even if less used in Italy. The wide use of ketamine, in this context, may be useful in defining its safety profile in children.

A retrospective 7-year study was conducted by Oxford University where procedural sedation with ketamine was provided to 215 children (median age of 4 years). In 87% of cases, ketamine was administered intravenously and 9.8% of patients had an ‘adverse outcome’, of which agitation and apnoea were the most common.

Bellolio et al. provided a systematic review and meta-analysis reporting rates of adverse events for commonly used sedation drugs in the ED, including ketamine. More than 13,000 cases of procedural sedations in children were evaluated comparing sedo-analgesia with ketamine alone or in combination with other drugs; the following adverse events were the most common: vomiting (8.9%), agitation (2.4%), hypoxia (1.3%), and apnoea, bradycardia, laryngospasm and drooling (all <1%). However, the use of ketamine in children <2 years can be associated with a high rate of uncommon airway and respiratory adverse events.

The i.v. route represents the principal mode of ketamine administration in procedural sedo-analgesia but a pain-free alternative to i.v. insertion has to be considered by clinicians for children. As alternative routes, a small number of studies evaluated rectal, intranasal and submucosal administration in the paediatric setting (Table 1). The rectal ketamine route was suggested in a clinical trial by Nilsson et al. performing sedation and analgesia in 61 children with cerebral palsy. In this case, the study protocol provided a combination of local anaesthetic paracetamol cream administered orally or rectally as well as midazolam (up to 0.4 mg/kg) and racemic ketamine (up to 5 mg/kg) both administered rectally. No serious events were reported and moderate sedation and analgesia were achieved.

Even if no sufficient data are available to recommend intranasal ketamine for sedation in children, a systematic review of randomized trials showed that intranasal ketamine on children undergoing procedural sedo-analgesia provided superior sedation to comparators and resulted in adequate sedation for 148/175 (85%) of participants. Intranasal ketamine administration was generally well tolerated with mild adverse effects, with vomiting being the most commonly reported by 9 out of 91 (10%) participants.

In another randomized clinical trial, the effectiveness of a submucosal administration of ketamine to induce sedoanalgesia in child candidates for diagnostic-therapeutic procedures was evaluated. Results showed that 4 and 3 mg/kg of submucosal ketamine are appropriate alternatives to i.v. ketamine. Rayala et al. have also investigated the efficacy of oral ketamine administration in procedural analgesia in paediatric cancer patients undergoing lumbar puncture and bone marrow aspirations. These studies were conducted in a resource-limited hospital setting and, according to the results, oral ketamine could be defined as an option for lumbar puncture; bone marrow aspiration is defined as a painful and stressful procedure and oral ketamine is not sufficient.

The different ketamine dosages used accordingly to the different administration routes are reported in Table 2.

**Ketamine and procedural pain in PPC: expert opinion**

Children receiving PPC often require invasive measures (e.g. insertion of venous catheter, such as midline, pleural or abdominal drainage tubes, bladder catheter) that are performed outside the intensive care setting, thus needing the management of the consequent procedural pain.

Literature evidence in the paediatric setting, in particular the safety data collected in the paediatric ED context, suggests that ketamine should be considered as a promising alternative option for procedural sedo-analgesia also in the PPC setting. Compared with the combination of opioids/benzodiazepines, ketamine may be considered a more manageable drug, with a favourable tolerability profile associated with a lower burden of adverse events, especially at the respiratory level. These characteristics make the use of ketamine possible also outside the surgical theater. Moreover, due to patients’ complex conditions, standard routes of administration (i.v. or intramuscular) for sedo-analgesia are sometimes not adequate. The possibility of using alternative routes of administration (in particular intranasally and submucosally) is an additional reason that makes ketamine a viable alternative option for procedural sedo-analgesia in the home PPC setting, for instance, in patients with difficult venous access.

**Ketamine and refractory status epilepticus**

The annual incidence of status epilepticus in childhood is estimated at 10.5–42 per 100,000, often representing a lifelong and life-threatening condition. The most common causes of epilepsy include prenatal injury, developmental and genetic disorders, neurological impairment head trauma, and infectious disease. Between 15% and 30% of cases are refractory to conventional therapies and are defined as refractory status epilepticus (RSE) when not responding to first-line and second-line antiepileptic drugs. The management of RSE represents a major challenge for paediatric physicians and a source of distress for families.

Seizure perpetuation in status epilepticus is due to mechanisms such as the internalization of γ-aminobutyric acid type A receptors and increased expression of NMDA receptor to the synapse. Ketamine was proposed as an effective drug in status epilepticus due to its anticonvulsant effects and its potential to prevent glutamate-mediated neurotoxicity,
Consequently, some authors proposed ketamine as a promising option for treating RSE in children (Table 1).\textsuperscript{57} A retrospective study was recently conducted on 18 children with RSE who received ketamine in intensive care unit of Beijing Children’s Hospital, divided into the loading-maintenance group (7 patients) and the maintenance group (11 patients). RSE was controlled with ketamine in 11 children (all patients in the loading-maintenance group and four in the maintenance group), without relevant adverse reactions, showing a significantly greater effectiveness of the loading-maintenance protocol. Despite it being a very small study, it suggested the effectiveness of ketamine for RSE control in children.\textsuperscript{58}

Rosati et al. adopted a protocol for RSE, including i.v. ketamine infusion. Midazolam was also administered to prevent emergence reactions. In a retrospective study over a period of nearly 2 years, nine children with RSE were treated with ketamine infusion, with a successful response in 70\% of cases. The median dose of ketamine in continuous i.v. infusion was 40 µg/kg/min. None of the patients experienced serious adverse events.\textsuperscript{59}

Despite these encouraging results, more research and larger studies are necessary to evaluate ketamine efficacy, safety and dosage in RSE treatment in children.\textsuperscript{60} For instance, a multicentre, randomized controlled study has been carried out in Italy to assess the efficacy of ketamine compared with conventional antiepileptic drugs in the treatment of RSE in children. In total, 57 patients (aged from 1 month to 18 years) were enrolled and were randomized to the control or experimental arms; the results are not yet available to our knowledge.\textsuperscript{61} Of note, it has been underlined that the use of ketamine in children affected by RSE avoids the pitfalls and dangers of endotracheal intubation, which is known to worsen RSE prognosis.\textsuperscript{62}

**Ketamine for the treatment of RSE in PPC: expert opinion**

In a recent cross-sectional survey, approximately 40\% of PPC patients were affected by a neurological disease\textsuperscript{63} and around half of all children with cerebral palsy have epilepsy. Amongst children with this condition, epilepsy is characterized by the following features: early onset, high frequency, presence of multiple seizure types, increasing drug resistance, low remission rates, high recurrence of seizures and status epilepticus, mortality.\textsuperscript{64,65} Consequently, seizure control is a recurrent problem in PPC setting and has a great impact on patient quality of life. Due to its pharmacological properties, ketamine could be a suitable option after the failure of conventional drugs in the treatment of RSE in children eligible for PPC such as those with rare diseases and those with severe cerebral palsy.

---

**Table 2. Ketamine dosage in paediatric patients.**

| Administration route | Dosage                                                                 |
|---------------------|------------------------------------------------------------------------|
| Intravenous         | **Sedation**<br>1–2 mg/kg, then if needed 0.5–1 mg/kg/dose (maximum 25 mg)\textsuperscript{76} |
|                     | **Analgesia**<br>0.5 mg/kg (repeated doses may be needed after 1–2 hours) or 0.05–0.5 mg/kg/h\textsuperscript{71,76} |
|                     | **Resistant depression**<br>0.5 mg/kg intravenously twice weekly; not to exceed 6 weeks\textsuperscript{72} |
|                     | **Refractory status epilepticus**<br>Loading dose 1.5 mg/kg, 2.2–2.4 mg/kg/h\textsuperscript{77} |
| Intramuscular       | **Sedation**<br>3–4 mg/kg, then if needed 2–4 mg/kg (63)                |
| Intranasal          | **Analgesia**<br>1 mg/kg\textsuperscript{78}                            |
| Oral administration | **Analgesia**<br>0.25–1 mg/kg/dose\textsuperscript{79}                 |
|                     | **Sedation**<br>5–10 mg/kg\textsuperscript{76}                          |
| Rectal              | **Analgesia**<br>5–6 mg/kg, mixture of racemic ketamine\textsuperscript{80} |
**Conclusion**

In the PPC setting, the clinical conditions could be hugely different and complex. Clinicians deal with many conditions that exhibit a high degree of drug resistance; several different organic dysfunctions, psychological alterations and suffering need to be treated. The assessment and management of pain represent primary objectives in PPC but also diagnostic and therapeutic procedures and neurological impairment represent a daily challenge. In our opinion, the use of ketamine in PPC should be more widely considered due to its overall favourable safety profile and its efficacy, which are supported by an increasing number of studies, although in settings different from PPC and of mixed quality. Ketamine should be proposed according to a case-by-case evaluation according to the specific diagnosis, and the dosage and route of administration should be tailored to the specific patient needs. Furthermore, some evidence suggests the safety and efficacy of ketamine in acute pain\(^6\); these findings can prompt further research on the use of ketamine for the treatment of acute pain in PPC.

Status epilepticus represents another clinical condition frequently observed in the PPC setting and it is, in many cases, refractory to conventional pharmacological treatments. Considering the encouraging data in the paediatric setting, the use of ketamine to treat RSE in PPC should certainly be further investigated to provide an additional treatment option.

Patients in PPC often develop physical and psychological sequelae due to their disease and treatment. Psychiatric issues and, in particular, depression and anxiety are reported in up to 30% of this population.\(^6\) Oral ketamine is effective in treating resistant depression in adult patients.\(^68\)–\(^70\) Although scant information is available for adolescents and children,\(^71\)\(^72\) and, to our knowledge, no data are available in the PPC setting, ketamine might be investigated in the treatment of depression and anxiety in PPC. Due to the interaction of ketamine with many receptors, the drug’s effects have also been explored for other indications such as bronchial asthma exacerbations.\(^73\) In addition, in the PC setting, children could experience airway obstruction and dyspnoea for many clinical reasons due to mediastinal or pulmonary mass, pleural effusion and heart failure.\(^74\)\(^75\) Therefore, ketamine should also be considered in this setting.

Ketamine also has the advantage of being a relatively inexpensive drug and could be used for several clinical conditions. Therefore, it could be useful to propose a standardized approach to ketamine use in PPC patients, both in the hospital and home-care setting, following the failure of conventional treatments. We believe that a more comprehensive evaluation of ketamine in patients with neuropathic and mixed pain could be of particular interest.

---

**Contributions:** SG and SP contributed to the literature research and wrote the first draft. All other authors have critically contributed to the analysis of evidence and provided major intellectual input to the paper. All authors have read and approved the final version of the paper before submission.

**Disclosure and potential conflicts of interest:** The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts and honoraria. All authors have approved the version to be published. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/04/dic.2021-2-5-COI.pdf

**Acknowledgements:** None.

**Funding declaration:** There was no funding associated with the preparation of this article.

**Copyright:** Copyright © 2021 Benini F, Congedi S, Giacomelli L, Papa S, Shah A, Milani G. Published by Drugs in Context under Creative Commons License Deed CC BY ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

**Correct attribution:** Copyright © 2021 Benini F, Congedi S, Giacomelli L, Papa S, Shah A, Milani G. https://doi.org/10.7573/dic.2021-2-5. Published by Drugs in Context under Creative Commons License Deed CC BY ND 4.0.

**Article URL:** https://www.drugsincontext.com/refractory-symptoms-in-paediatric-palliative-care:-can-ketamine-help?

**Correspondence:** Franca Benini, Centro Regionale Veneto di Terapia del Dolore and Cure Palliative Pediatriche, Hospice Pediatrico, Padua, Italy. Email: franca.benini@aopd.veneto.it

**Provenance:** Submitted; externally peer reviewed.

**Submitted:** 23 February 2021; **Accepted:** 15 April 2021; **Publication date:** 19 May 2021.

**Drugs in Context** is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com
References

1. Fraser LK, Miller M, Hain R, et al. Rising national prevalence of life-limiting conditions in children in England. Pediatrics. 2012;129(4):e923–929. https://doi.org/10.1542/peds.2011-2846

2. Goldman A. ABC of palliative care. Special problems of children. BMJ. 1998;316(7124):49–52. https://doi.org/10.1136/bmj.316.7124.49

3. World Health Organization. Cancer Pain Relief and Palliative Care in Children. 1998. https://www.who.int/cancer/palliative/definition/en/. Accessed April 26, 2021.

4. Norris S, Minkowitz S, Scharbach K. Pediatric palliative care. Prim Care. 2019;46(3):461–473. https://doi.org/10.1016/j.pop.2019.05.010

5. Nilsson S, Ohlen J, Hesselman E, Brännström M. Paediatric palliative care: a systematic review. BMJ Support Palliat Care. 2020;10:157–163. https://doi.org/10.1136/bmjspcare-2019-001934

6. Sisk BA, Feudtner C, Bluebond-Langner M, Sourkes B, Hinds PS, Wolfe J. Response to suffering of the seriously ill child: a history of palliative care for children. Pediatrics. 2020;145(1):e20191741. https://doi.org/10.1542/peds.2019-1741

7. Splinter W. Novel approaches for treating pain in children. Curr Oncol Rep. 2019;21(2):11. https://doi.org/10.1007/s11991-019-00766-6

8. De Zen L, Marchetti F, Barbi E, Benini F. Paediatric palliative care and off-label drug use. Med Bambino. 2019;38:97–102.

9. Di Mascio A, Bossini B, Barbi E, Benini F, Cozzi G. Use of ketamine by paediatricians in Italian paediatric emergency departments: a missed opportunity? Eur J Pediatr. 2019;178(4):587–591. https://doi.org/10.1007/s00431-019-03320-z

10. Dorandeu F. Happy 50th anniversary ketamine. CNS Neurosci Ther. 2013;19(6):369. https://doi.org/10.1111/cns.12074

11. Mion G. History of anaesthesia: the ketamine story – past, present and future. Eur J Anaesthesiol. 2017;34(9):571–575. https://doi.org/10.1097/EJA.0000000000000638

12. Mueller RA, Hunt R. Antagonism of ketamine-induced anaesthesia by an inhibitor of nitric oxide synthesis: a pharmacokinetic explanation. Pharmacol Biochem Behav. 1998;60(1):15–22. https://doi.org/10.1016/S0091-3057(97)00450-4

13. Zhao J, Wang Y, Wang D. The effect of ketamine infusion in the treatment of complex regional pain syndrome: a systemic review and meta-analysis. Curr Pain Headache Rep. 2018;22(2):12. https://doi.org/10.1007/s11916-018-0664-x

14. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain. 2008;24:479–496. https://doi.org/10.1097/AJP.0b013e31816b2f43

15. DuPen A, Shen D, Ersek M. Mechanisms of opioid-induced tolerance and hyperalgesia. Pain Manag Nurs. 2007;8:113–121. https://doi.org/10.1016/j.pmn.2007.02.004

16. Wolfe J, Orellana L, Ullrich C, et al. Symptomatic and distress in children with advanced cancer: prospective patient-reported outcomes from the PediQUEST study. J Clin Oncol. 2015;33(17):1928–1935. https://doi.org/10.1200/JCO.2014.59.1222

17. Hechler T, Blankenburg M, Friedrichsdorf SJ, et al. Parents’ perspective on symptoms, quality of life, characteristics of death and end-of-life decisions for children dying from cancer. Klin Padiatr. 2008;220(3):166–174. https://doi.org/10.1055/s-2008-1065347

18. Heath JA, Clarke NE, Donath SM, et al. Symptoms and suffering at the end of life in children with cancer: an Australian perspective. Med J Aust. 2010;192(2):71–75. https://doi.org/10.5694/j.1326-5377.2010.tb03420.x

19. Courade M, Bertrand A, Guerrini-Rousseau L, et al. Low-dose ketamine adjuvant treatment for refractory pain in children, adolescents and young adults with cancer: a pilot study. BMJ Support Palliat Care. 2019. https://doi.org/10.1136/bmjspcare-2018-001739

20. Angehelescus DL, Tesney JM. Neuropathic pain in pediatric oncology: a clinical decision algorithm. Pediatr Drugs. 2019;21(2):59–70. https://doi.org/10.1007/s40272-018-00324-4

21. Bredlau AL, Thakur R, Korones DN, Dworkin RH. Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature. Pain Med. 2013;14(10):1505–1517. https://doi.org/10.1111/pme.12182

22. Taylor M, Jakacci R, May C, Howrie D, Maurer S. Ketamine PCA for treatment of end-of-life neuropathic pain in pediatrics. Am J Hosp Palliat Care. 2015;32(8):841–848. https://doi.org/10.1177/1049909114534640

23. Finkel JC, Pestieau SR, Quezado ZMN. Ketamine as an adjuvant for treatment of cancer pain in children and adolescents. J Pain. 2007;8(6):515–521. https://doi.org/10.1016/j.jpain.2007.02.029

24. Klepstad P, Borchgrevink P, Hval B, Flaat S, Kaasa S. Long-term treatment with ketamine in 12-year-old girl with severe neuropathic pain caused by a cervical spinal tumor. J Pediatr Hematol Oncol. 2001;23(9):616–619. https://doi.org/10.1097/00004342-20011200-00013

25. Conway M, White N, St Jean C, Zempsky WT, Steven K. Use of continuous intravenous ketamine for end-stage cancer pain in children. J Pediatr Oncol Nurs. 2009;26(2):100–106. https://doi.org/10.1177/104354208328768

26. Tsui BCH, Davies D, Desai S, Malherbe S. Intravenous ketamine infusion as an adjuvant to morphine in a 2-year-old with severe cancer pain from metastatic neuroblastoma. J Pediatr Hematol Oncol. 2004;26(10):678–680.

27. Michelet D, Hilly J, Skhiri A, et al. Opioid-sparing effect of ketamine in children: a meta-analysis and trial sequential analysis of published studies. Paediatr Drugs. 2016;18(6):421–433. https://doi.org/10.1007/s40272-016-0196-y

Benini F, Congedi S, Giacomelli L, et al. Drugs in Context 2021; 10: 2021-2-5. DOI: 10.7573/dic.2021-2-5

ISSN: 1740-4398
28. Lubega FA, DeSilva MS, Munube D, et al. Low dose ketamine versus morphine for acute severe vaso occlusive pain in children: a randomized controlled trial. *Scand J Pain*. 2018;18(1):19–27. https://doi.org/10.1515/sjpain-2017-0140

29. Hagedorn JM, Monico EC. Ketamine infusion for pain control in acute pediatric sickle cell painful crises. *Pediatr Emerg Care*. 2019;35(1):78–79. https://doi.org/10.1097/PEC.0000000000000978

30. Rayala S, Bäckdahl T, Reddy N, et al. Low-dose oral ketamine for procedural analgesia in pediatric cancer patients undergoing lumbar puncture at a resource-limited cancer hospital in India. *J Palliat Med*. 2019;22(11):1357–1363. https://doi.org/10.1089/jpam.2018.0667

31. Yenigun A, Yılmaz S, Dogan R, Göktas SS, Calım M, Ozturan O. Demonstration of analgesic effect of intranasal ketamine and intranasal fentanyl for postoperative pain after pediatric tonsillectomy. *Int J Pediatr Otorhinolaryngol*. 2018;104:182–185. https://doi.org/10.1016/j.ijpolar.2017.11.018

32. Azizkhani R, Esmaillian M, Shojaei A, Golshani K. Rectal thiopental versus intramuscular ketamine in pediatric procedural sedation and analgesia; a randomized clinical trial. *Emergency*. 2015;3:22–26.

33. Gelen SA, Sarper N, Demirsoy U, Zengin E, Çakmak E. The efficacy and safety of procedural sedoanalgesia with midazolam and ketamine in pediatric hematology. *Turk J Haematol*. 2015;32(4):351–354. https://doi.org/10.4274/tjh.2014.0149

34. Hu Y, Xu W, Cao F. A meta-analysis of randomized controlled trials: combination of ketamine and propofol versus ketamine alone for procedural sedation and analgesia in children. *Intern Emerg Med*. 2019;14(7):1159–1165. https://doi.org/10.1007/s11739-019-02173-6

35. Green SM, Johnson NE. Ketamine sedation for pediatric procedures: part 2, review and implications. *Ann Emerg Med*. 1990;19(9):1033–1044. https://doi.org/10.1016/S0196-0644(05)82569-7

36. Kidd LR, Lyons SC, Lloyd G. Paediatric procedural sedation using ketamine in a UK emergency department: a 7-year review of practice. *Br J Anaesth*. 2016;116(4):518–523. https://doi.org/10.1093/bja/aev555

37. Bellolio MF, Puls HA, Anderson JL, et al. Incidence of adverse events in paediatric procedural sedation in the emergency department: a systematic review and meta-analysis. *BMJ Open*. 2016;6(6):e011384. https://doi.org/10.1136/bmjopen-2016-011384

38. Green SM, Roback MG, Krauss B, et al. Predictors of airway and respiratory adverse events with ketamine sedation in the emergency department: an individual-patient data meta-analysis of 8,282 children. *Ann Emerg Med*. 2009;54(2):158–168.e1-4. https://doi.org/10.1016/j.annemergmed.2008.12.011

39. vadivelu N, Scherer E, Kodumudi V, Belani K, Urman RD, Kaye AD. Role of ketamine for analgesia in adults and children. *J Anaesthesiol Clin Pharmacol*. 2016;32(2):298–306. https://doi.org/10.4103/0970-9185.168149

40. Grossmann B, Nilsson A, Sjöberg F, Nilsson L. Rectal ketamine during paediatric burn wound dressing procedures: a randomised dose-finding study. *Burns*. 2019;45(5):1081–1088. https://doi.org/10.1016/j.burns.2018.12.012

41. Nilsson S, Brunsson I, Askljung B, Pålman M, Himmelmann K. A rectally administered combination of midazolam and ketamine was easy, effective and feasible for procedural pain in children with cerebral palsy. *Acta Paediatr*. 2017;106(3):458–462. https://doi.org/10.1111/apa.13710

42. Del Pizzo J, Callahan JM. Intranasal medications in pediatric emergency medicine. *Pediatr Emerg Care*. 2014;30(7):496–501; quiz 502–504. https://doi.org/10.1097/PEC.0000000000000171

43. Murphy AP, Hughes M, McCooy S, Crispino G, Wakai A, O'Sullivan R. Intranasal fentanyl for the prehospital management of acute pain in children. *Burns*. 2017;43(6):450–454. https://doi.org/10.1016/j.burns.2016.011384

44. Poonai N, Canton K, Ali S, et al. Intranasal ketamine for procedural sedation and analgesia in children: a systematic review. *Pediatr Emerg Care*. 2014;30(7):496–501; quiz 502–504. https://doi.org/10.1097/PEC.0000000000000171

45. Nemeth M, Jacobsen N, Bantel C, Fieller M, Sümpelmann R, Eich C. Intranasal analgesia and sedation in pediatric emergency medicine. *Pediatr Emerg Care*. 2018;34(6):606–613. https://doi.org/10.1097/PEC.000000000000171

46. Majidinejad S, Ebrahimi M, Azizkhani R, et al. The effects of different doses of submucosal vs. intravenous ketamine for conscious-sedation in children candidates for diagnostic-therapeutic procedures in emergency department. *Front Emerg Med*. 2021;5(1):e5.

47. Rayala S, Kyander M, Haridass V. Low-dose oral ketamine as a procedural analgesia in pediatric cancer patients undergoing bone marrow aspirations at a resource-limited cancer hospital in India. *Indian J Palliat Care*. 2019;25(4):501–507. https://doi.org/10.4103/IJPC.IJPC_110_19

48. Aroni F, Iacovidou N, Dontas I, Pourzitaki C, Xanthos T. Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug. *J Clin Pharmacol*. 2009;49(8):957–964. https://doi.org/10.1177/009127009337941

49. Pourmand A, Mazeri-Amidishi M, Royall C, Alhawas R, Shesser R. Low dose ketamine use in the emergency department, a new direction in pain management. *Am J Emerg Med*. 2017;35(6):918–921. https://doi.org/10.1016/j.ajem.2017.03.005

50. Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. *Epilepsia*. 2015;56(10):1515–1523. https://doi.org/10.1111/epi.13121

51. Epilepsy foundation and epilepsy together. https://www.epilepsy.com/learn/professionals/co-existing-disorders/developmental-disorders/mental-retardation-and-cerebral-7. Accessed April 26, 2021.
52. Abend NS, Dlugos DJ. Treatment of refractory status epilepticus: literature review and a proposed protocol. Pediatr Neurol. 2008;38(6):377–390. https://doi.org/10.1016/j.pediatrneurol.2008.01.001

53. DeCourcy DD, Silverman M, Oladunjoye A, Balkin EM, Wolfe J. Patterns of care at the end of life for children and young adults with life-threatening complex chronic conditions. J Pediatr. 2018;193:196–203.e2. https://doi.org/10.1016/j.jpeds.2017.09.078

54. Höfler J, Trinka E. Intravenous ketamine in status epilepticus. Epilepsia. 2018;59(Suppl. 2):198–206. https://doi.org/10.1111/epi.14480

55. Fujikawa DG. Neuroprotective effect of ketamine administered after status epilepticus onset. Epilepsia. 1995;36(2):186–195. https://doi.org/10.1111/j.1528-1157.1995.tb00979.x

56. Tasker RC, Vitali SH. Continuous infusion, general anesthesia and other intensive care treatment for uncontrolled status epilepticus. Curr Opin Pediatr. 2014;26(6):682–689. https://doi.org/10.1097/MOP.0000000000000149

57. Wu J, Wang Q, Qian SY, et al. Efficacy and safety of ketamine in refractory status epilepticus in children, Zhonghua Er Ke Za Zhi. 2020;58(4):295–300. https://doi.org/10.3760/cma.j.cn112140-20191128-00759

58. Rosati A, L’Erario M, Ilvento L, et al. Efficacy and safety of ketamine in refractory status epilepticus in children. Neurology. 2012;79(24):2355–2358. https://doi.org/10.1212/WNL.0b013e318278b685

59. Rosati A, De Masi S, Guerrini R. Ketamine for refractory status epilepticus: a systematic review. CNS Drugs. 2018;32(11):997–1009. https://doi.org/10.1007/s40263-018-0569-6

60. Rosati A, Ilvento L, L’Erario M, et al. Efficacy of ketamine in refractory convulsive status epilepticus in children: a protocol for a sequential design, multicentre, randomised, controlled, open-label, non-profit trial (KETASER01). BMJ Open. 2016;6(6):e011565. https://doi.org/10.1136/bmjopen-2016-011565

61. Ilvento L, Rosati A, Marini C, L’Erario M, Mirabile L, Guerrini R. Ketamine in refractory convulsive status epilepticus in children avoids endotracheal intubation. Epilepsia Behav. 2015;49:343–346. https://doi.org/10.1016/j.yebeh.2015.06.019

62. Pisani F, Prezioso G, Spagnoli C. Neonatal seizures in preterm infants: a systematic review of mortality risk and neurological outcomes from studies in the 2000’s. Seizure. 2020;75:7–17. https://doi.org/10.1016/j.seizure.2019.12.005.

63. Ronen GM, Buckley D, Streiner DL. Long-term prognosis in children with neonatal seizures: a population-based study. Neurology. 2007;69(19):1816–1822. https://doi.org/10.1212/01.wnl.0000279335.85797.2c

64. Levine DR, Mandrell BN, Sykes A, et al. Patients’ and parents’ needs, attitudes, and perceptions about early palliative care integration in pediatric oncology. JAMA Oncol. 2017;3(9):1214–1220. https://doi.org/10.1001/jamaoncol.2017.0368

65. Ferguson CL, Beckett RD. Intranasal ketamine for treatment of acute pain in pediatrics: a systematic review. Pediatr Emerg Care. 2020;36(8):e476-e481. https://doi.org/10.1097/PEC.0000000000002181

66. Hartberg J, Garrett-Walcott S, De Gioannis A. Impact of oral ketamine augmentation on hospital admissions in children with life-threatening complex chronic conditions. Br J Psychiatry. 2019;214(1):20–26. https://doi.org/10.1192/bjp.2018.196

67. Jafarinia M, Afarideh M, Tafakhori A, et al. Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial. J Affect Disord. 2016;204:1–8. https://doi.org/10.1016/j.jad.2016.05.076

68. Domany V, Bleich-Cohen M, Tarrasch R, et al. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study. Br J Psychiatry. 2019;214(6):371–378. https://doi.org/10.1192/bjp.2018.0428

69. Zarrinnegar P, Kothari J, Cheng K. Successful use of ketamine for the treatment of psychotic depression in a teenager. J Child Adolesc Psychopharmacol. 2019;29(6):472–473. https://doi.org/10.1089/cap.2019.0028

70. Cullen KR, Amatya P, Roback MG, et al. Intravenous ketamine for adolescents with treatment-resistant depression: an open-label study. J Child Adolesc Psychopharmacol. 2018;28(7):437–444. https://doi.org/10.1089/cap.2018.0030

71. Tran K, McCormack S. Ketamine for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health; May 28, 2020. https://www.ncbi.nlm.nih.gov/books/NBK564230/

72. Chen CH, Wu KH, Chao YH. Clinical manifestation of pediatric mediastinal tumors, a single center experience. Medicine (Baltimore). 2019;98(32):e16732. https://doi.org/10.1016/j.mdac.2019.07.008

73. Wolfe J, Grier HE, Klar N, Levin SB. Symptoms and suffering at the end of life in children with cancer. N Engl J Med. 2000;342(5):326–333. https://doi.org/10.1056/NEJM200002033420506

74. The Royal Children’s Hospital Melbourne. Clinical Practice Guidelines. https://www.rch.org.au/clinicalguide/guideline_index/Ketamine_use_for_procedural_sedation. Accessed April 26, 2021.

75. Graudins A, Meek R, Egerton-Warburton D, Oakley E, Seith R. The PICHFORK (Pain in Children Fentanyl or Ketamine) trial: a randomized controlled trial comparing intranasal ketamine and fentanyl for the relief of moderate to severe pain in children with limb injuries. Ann Emerg Med. 2015;65(3):248–254.e1. https://doi.org/10.1016/j.annemergmed.2014.09.024

76. Bredlau AL, McDermott MP, Adams HR, et al. Oral ketamine for children with chronic pain: a pilot phase 1 study. J Pediatr. 2013;163(1):194–200.e1. https://doi.org/10.1016/j.jpeds.2012.12.077